LUGANO, Switzerland • The Proveo offer of a “one-stop-shop” for Antibody Drug Conjugate (ADC) development, manufacturing and delivery is now restructured as a fully integrated business division of Cerbios-Pharma SA. The restructuring ensures that the service can meet the complex supply chain and program management requirements for successful ADC Drug Product manufacturing, allowing it to provide a…
LUGANO, Switzerland • Pharmaceutical CDMO specialist Cerbios-Pharma SA (Cerbios) will again be a key presence at the 12th World ADC conference Digital San Diego Edition happening from the .11th to the 14th October. Cerbios will be presenting its Proveo division in the CMC stream and in the virtual booth promoting advanced integrated solutions in antibody drug conjugates.…
LUGANO, June 28th, 2021 • Swissmedic approved Cerbios’ new HPAPI plant Cerbios-Pharma is pleased to announce the approval by Swissmedic of its new HPAPI plant, which forms the latest addition to its plan of expansion into the manufacture of highly potent drug substances. This new production line is dedicated to highly active products with containment…
LUGANO, April 7th, 2020 • From April 1st 2020 the 400 MHz NMR is fully operational in Cerbios. The new equipment expands Cerbios’s already outstanding analytical chemistry capabilities, which now comprise the 400 MHz NMR, HR-Q-TOF mass spectrometer, DSC and UPLCs in addition to all of the most common equipment and techniques. The new instrument…
LUGANO, December 20th, 2019 • Cerbios is proud to announce successful SwissMedic authorization of its new cGMP bioconjugation suite for up-to commercial scale manufacturing of Antibody Drug Conjugates (ADCs). “The suite further expands Cerbios’ ADCs capacities and consolidates Cerbios commitment to provide best-in-class bioconjugation services for its partners worldwide” says Matteo Piazza Cerbios- Pharma BD…
LUGANO, October 1st, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Mr. Claudio Pozzoli has been promoted as Chief Operation Officer (COO) and Alberto Terraneo is our new R&D Director. Fausto Vellani (the former COO) has moved to the sister company, strengthening a team that is already achieving excellent results and…
LUGANO, March 18, 2019 • Thomas Matt, Senior Manager R&D Chemical Division at Cerbios, looks at some practical experiences in projects for ADC payloads. “During all stages of R&D activities, a process has to be developed, while also considering the containment system required and the design of the plant, so as to ensure reproducible manufacturing, of…
LUGANO, February 15, 2019 • Vitor Sousa, Senior Manager of R&D Biological Division at Cerbios, talks about the challenges that a CDMO has to solve while developing a robust and scalable process ready for cGMP production for clinical trials and later on for commercial supply. “Antibody-drug conjugates (ADCs) for oncology therapies are composed of an antibody…
LUGANO, January 18, 2019 • Cerbios-Pharma SA (from now on “Cerbios”) board of directors has approved the detailed design and budget for the installation in its High Potency Active Ingredients (HPAIs) dedicated building of a new production line able to accommodate larger volumes and batch size. Cerbios is active in the HPAI arena since 1993 with…
LUGANO, December 1st, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units. Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m3) started. In…
